Skip to main content
Premium Trial:

Request an Annual Quote

By Foundation Medicine

Foundation Medicine Study Shows Value of ctDNA Tumor Fraction for Treatment Response Monitoring in Clinical Research

The results add to evidence for the potential of ctDNA tumor fraction as a new monitoring tool that could allow clinical researchers to detect tumor progression and change treatment strategies earlier than through current methods.

By Guardant Health

DNA Methylation as a Biomarker of Cancer Therapy Response and Minimal Residual Disease: Trends, Challenges, and Use Cases

DNA methylation analysis in the blood, powered by advances in wet-lab chemistry and bioinformatics, has enabled the use of epigenomic profiling to enhance the sensitivity of liquid biopsy, providing a deeper understanding of tumor biology and expanding the promise of precision oncology beyond what genomic information can offer.

By Thermo Fisher Scientific

Perspective: Thermo Fisher Aims to Reduce Time-to-Results for Cancer NGS

For the benefits of precision medicine to be fully realized, more laboratories must be able to access NGS technologies in-house, and NGS results must be delivered to patients faster.

By Illumina

As Use of Large Cancer Panels and Whole-Genome Sequencing Expands, Illumina Plans to Future-Proof NGS Interpretation and Reporting

Illumina’s new software platform, designed to reduce tertiary analysis time and ease reporting, launches in multiple global markets as experts say the volume of clinical NGS data is ballooning. 


By Janssen

Perspective: Delivering Precision Medicine for Bladder Cancer Through Collaboration

In the wake of a transformational period for bladder cancer treatment, the time is right to harness integrated care coordination and precision medicine in order to optimize patient outcomes across the disease continuum. 

By Cullinan Oncology

A Platform-Agnostic Approach to Building a Diversified Immuno-Oncology Portfolio

Science Stock Image 3 - Pipeline_0.jpg

Platform- or modality-agnostic approaches to therapeutic agent design may offer more promise than platform-centric approaches. Rather than deploying a single strategy, researchers can allow the biology to dictate therapeutic design.

By Oxford BioDynamics

Q&A: How a Noninvasive Blood Test is Changing Immunotherapy Treatment

The noninvasive test evaluates eight 3D genomic markers and is the only test that returns a binary result to the ordering physician with high accuracy: “low probability” or “high probability” of response to an ICI.

By Tecan

Perspective: Enabling the Transition Between Research and Clinical Medicine in Oncology Testing With Automation

The translation of bench research into the clinical environment has accelerated significantly in recent years, highlighting the challenges of translating new techniques into regulated, scalable methodologies and increasing the need for clinically validated workflows.

By F. Hoffmann-La Roche Ltd.

Perspective: Accessing Innovation at the Point of Care with Comprehensive Genomic Profiling

Precision oncology will only be a reality for all patients if there is collaboration between the different stakeholders within the healthcare system — such as industry partners, academia, and regulatory bodies — to increase patient access.

By Biognosys

Next-Generation Proteomics Delivers Insights Across the Oncology Pipeline: Highlights from the AACR 2022 Annual Meeting

Advances in proteomics are improving cancer biomarker discovery, drug discovery, and drug target validation.